Thermo Fisher Reaches $11.5 Billion Deal to Acquire Qiagen

Thermo Fisher has entered into a $11.5 billion acquisition deal with molecular diagnostics developer Qiagen.

Qiagen develops sample preparation technologies used to extract, isolate and purify DNA, RNA and proteins from biological samples. The company reported revenues of $1.53 billion in 2019.

If finalized, the deal will help Thermo Fisher to expand its portfolio of specialty diagnostic products, including assays for infectious diseases.